Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference.
We will actively participate several parts of the event:
- On the 4th of May, Laurent Décory, COO of Aurealis Therapeutics, will co-chair Preparing for successful wound care clinical trials during EWMA Innovation Forum, with renowned speakers Kirsi Isoherranen, Simone Barbagallo and Alberto Piaggesi.
- On the 5th of May, Professor Christoph Schindler will present the results of AUP-16 DFU Phase 1 study and abstract 4-in-1 live biotherapeutic Gene Therapy Medicinal Product (GTMP) accelerates healing of Diabetic Foot Ulcers (DFU): a first-in-human, phase-1 clinical study during the Diabetic Foot session number 5.
- During the same day, Laurent Décory will present Aurealis Therapeutics company and platform during EWMA Innovation Forum pitch session number 3.
Participants to these sessions will be required to have a previous registration. Thus, it is important to save your place.
We look forward to meeting you in Milan!
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO